The bar for successful pharmaceutical launches has never been higher. Consider the facts that, according to IQVIA research, less than 10% of launches achieve international excellence across two or more countries, and over half of new launches generate less than $5 million in their first year in the top eight countries. Each launch demands a distinct approach shaped by the product’s context, whether it’s a specialty therapy targeting a rare disease or a mass-market breakthrough such as glucagon-like peptide-1 (GLP-1) drugs. Constrained health care systems and evolving engagement models present complexities that every successful strategy should address.

More products than ever are vying for attention amid pipeline growth intended to offset patent expirations. Product lifecycles continue to shorten, and the window to establish market position narrows with each new competitor.

Fortunately, agentic artificial intelligence (AI) is emerging as a powerful solution for many of the complex problems life sciences leaders face today. Agentic systems can process vast data streams in real time, adapt to shifting market conditions and support decisions across the entire launch lifecycle.

A framework for agentic-powered launches

Mastering four strategic pillars creates an effective, unified framework for agentic-powered launches. This framework captures how AI can serve as a catalyst for launch success, not only as a single tool but also as a strategic enabler across four tightly connected dimensions: planning, alignment, execution and intelligence.

Bringing the agentic framework to life

Consider a rare disease launch where patients are difficult to diagnose and even harder to find in secondary data.

In the planning phase, traditional patient prospecting might rely on broad physician outreach and hope that awareness translates into referrals. The challenge is twofold. Patients with rare conditions often go years without a definitive diagnosis code in their records. Additionally, the physicians best suited to treat them may not be readily apparent based solely on their specialty. Agentic and AI-enabled solutions address both problems by analyzing claims data, electronic medical records and laboratory results to identify patients whose clinical patterns suggest the condition while simultaneously identifying the physicians already managing their care. This helps companies find the right opportunities and creates more informed forecasts.

As the launch date approaches, alignment tools help coordinate activities across global and local teams. Rather than managing tasks through disconnected trackers, teams operate from a unified platform that provides real-time visibility and intelligence with recommendations to fill gaps with launch preparedness and readiness.

At launch, execution support ensures field teams know which physicians to prioritize based on the patient-finding work completed during planning. MSLs benefit from agent-powered platforms that streamline relationship management with the specialists most likely to encounter these patients. Promotional optimization tools help marketing teams stretch limited rare disease budgets further.

Throughout this journey, intelligence capabilities continuously monitor the market for signals relevant to the rare disease space, from competitor pipeline announcements to emerging real-world evidence. When new clinical data surfaces or a competitor adjusts their strategy, the system alerts the relevant team members. This situational awareness helps organizations respond proactively rather than discover competitive shifts weeks later in syndicated data reports.

Critical success factors for AI adoption

Organizations exploring agentic AI for launch optimization should consider three lessons from early implementations.

First, technology alone does not deliver results. The most successful deployments pair agentic capabilities with thoughtful change management that helps teams adapt workflows and embrace new ways of working. When field representatives understand how AI guidance complements their customer knowledge instead of replacing it, adoption accelerates.

Second, not every problem requires an agentic solution. Some challenges, particularly those requiring deep strategic context or brand-specific expertise, benefit more from consultative AI methods that keep humans firmly in the loop. The most sophisticated implementations match the right type of AI to each use case.

Third, human-AI collaboration should augment existing capabilities rather than replace them. Implementing “human-in-the-loop” supervision, especially in early deployments, allows teams to review and approve agent actions. This builds organizational confidence and ensures safety while demonstrating measurable value that supports broader adoption.

The intelligent launch engine is within reach

The pressure to execute flawlessly continues to intensify, whether the next launch is focused on a niche therapeutic area or aims for broad market impact. The agentic framework offers a way to close critical gaps in knowledge and agility, empowering teams to respond with speed and precision in an industry where both are essential. By leveraging agentic AI, organizations can navigate complexity and drive launch success with greater confidence. Ultimately, those who embrace intelligent, adaptive approaches will be best positioned to thrive in the evolving pharmaceutical landscape.

Natalie Harb is vice president, offering development – launch excellence; Vineet Purwar is principal, global launch excellence, both at IQVIA